S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cutera, Inc. stock logo
CUTR
Cutera
$2.30
-3.4%
$2.10
$1.28
$24.46
$47.47M1.661.72 million shs1.13 million shs
FONAR Co. stock logo
FONR
FONAR
$16.83
+1.8%
$21.17
$12.13
$24.05
$106.50M1.1219,134 shs19,269 shs
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
$37.15
-2.0%
$44.19
$3.16
$53.82
$1.21B-1.56300,015 shs262,210 shs
ViewRay, Inc. stock logo
VRAY
ViewRay
$0.34
$0.02
$4.96
$4.59M0.817.51 million shs108.50 million shs
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cutera, Inc. stock logo
CUTR
Cutera
-3.36%+19.17%+16.16%-16.36%-90.45%
FONAR Co. stock logo
FONR
FONAR
+1.85%-4.62%-20.41%-11.77%+4.50%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-1.98%-4.72%-14.93%-20.97%+877.63%
ViewRay, Inc. stock logo
VRAY
ViewRay
0.00%0.00%0.00%0.00%-97.93%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cutera, Inc. stock logo
CUTR
Cutera
0.7219 of 5 stars
3.31.00.00.00.01.70.6
FONAR Co. stock logo
FONR
FONAR
N/AN/AN/AN/AN/AN/AN/AN/A
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
4.156 of 5 stars
3.51.00.04.62.34.20.6
ViewRay, Inc. stock logo
VRAY
ViewRay
1.5125 of 5 stars
3.00.00.04.40.01.70.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cutera, Inc. stock logo
CUTR
Cutera
2.50
Moderate Buy$14.75541.30% Upside
FONAR Co. stock logo
FONR
FONAR
N/AN/AN/AN/A
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3.00
Buy$55.6049.66% Upside
ViewRay, Inc. stock logo
VRAY
ViewRay
2.00
Hold$1.33∞ Upside

Current Analyst Ratings

Latest SLNO, FONR, CUTR, and VRAY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/22/2024
Cutera, Inc. stock logo
CUTR
Cutera
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$10.00
3/22/2024
Cutera, Inc. stock logo
CUTR
Cutera
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderperform ➝ Market Perform
3/6/2024
Cutera, Inc. stock logo
CUTR
Cutera
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$10.00
2/5/2024
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$93.00
1/23/2024
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$63.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cutera, Inc. stock logo
CUTR
Cutera
$230.18M0.20N/AN/A($8.01) per share-0.29
FONAR Co. stock logo
FONR
FONAR
$98.64M1.08$2.79 per share6.04$23.07 per share0.73
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/A$5.16 per shareN/A
ViewRay, Inc. stock logo
VRAY
ViewRay
$105.86M0.00N/AN/A$0.45 per share0.00

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cutera, Inc. stock logo
CUTR
Cutera
-$150.83M-$7.34N/AN/AN/A-68.87%N/A-34.04%5/14/2024 (Estimated)
FONAR Co. stock logo
FONR
FONAR
$9.38M$1.849.14N/A12.63%8.47%6.45%5/20/2024 (Estimated)
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$38.99M-$2.97N/AN/AN/AN/A-79.65%-52.92%5/14/2024 (Estimated)
ViewRay, Inc. stock logo
VRAY
ViewRay
-$107.33M-$0.60N/AN/AN/A-104.30%-120.48%-42.39%N/A

Latest SLNO, FONR, CUTR, and VRAY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/21/2024Q4 2023
Cutera, Inc. stock logo
CUTR
Cutera
-$1.20-$2.27-$1.07-$2.27$49.10 million$49.54 million
3/6/2024Q4 2023
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$0.31-$0.33-$0.02-$0.33N/AN/A
3/5/2024Q3 2023
Cutera, Inc. stock logo
CUTR
Cutera
N/A-$2.22-$2.22-$2.22N/A$46.48 million
2/14/2024Q2 2024
FONAR Co. stock logo
FONR
FONAR
N/A$0.54+$0.54$0.54N/A$25.39 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cutera, Inc. stock logo
CUTR
Cutera
N/AN/AN/AN/AN/A
FONAR Co. stock logo
FONR
FONAR
N/AN/AN/AN/AN/A
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/AN/A
ViewRay, Inc. stock logo
VRAY
ViewRay
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cutera, Inc. stock logo
CUTR
Cutera
N/A
3.17
2.44
FONAR Co. stock logo
FONR
FONAR
N/A
9.35
9.15
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/A
14.89
14.89
ViewRay, Inc. stock logo
VRAY
ViewRay
N/A
1.16
0.91

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Cutera, Inc. stock logo
CUTR
Cutera
90.70%
FONAR Co. stock logo
FONR
FONAR
50.64%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
97.42%
ViewRay, Inc. stock logo
VRAY
ViewRay
92.97%

Insider Ownership

CompanyInsider Ownership
Cutera, Inc. stock logo
CUTR
Cutera
2.10%
FONAR Co. stock logo
FONR
FONAR
8.58%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
23.70%
ViewRay, Inc. stock logo
VRAY
ViewRay
2.50%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Cutera, Inc. stock logo
CUTR
Cutera
54019.94 million19.53 millionOptionable
FONAR Co. stock logo
FONR
FONAR
5616.33 million5.79 millionNot Optionable
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3332.46 million24.77 millionOptionable
ViewRay, Inc. stock logo
VRAY
ViewRay
295183.40 million178.82 millionOptionable

SLNO, FONR, CUTR, and VRAY Headlines

SourceHeadline
The best 4K Blu-ray players for 2024The best 4K Blu-ray players for 2024
digitaltrends.com - March 24 at 6:22 PM
VRAY Jan 2025 2.000 callVRAY Jan 2025 2.000 call
finance.yahoo.com - March 16 at 9:28 AM
VRAY Jan 2025 0.500 putVRAY Jan 2025 0.500 put
finance.yahoo.com - March 16 at 9:28 AM
VRAY Jan 2025 0.500 callVRAY Jan 2025 0.500 call
finance.yahoo.com - March 16 at 12:50 AM
VRAY Jan 2025 3.000 putVRAY Jan 2025 3.000 put
finance.yahoo.com - March 16 at 12:50 AM
Creating the Scene with V-Ray for 3ds MaxCreating the Scene with V-Ray for 3ds Max
archdaily.com - March 2 at 1:34 PM
How to Supercharge Your SketchUp Renders With V-Ray Lights and MaterialsHow to Supercharge Your SketchUp Renders With V-Ray Lights and Materials
archdaily.com - February 26 at 6:18 PM
ViewRay Inc VRAYQViewRay Inc VRAYQ
morningstar.com - November 4 at 7:06 AM
NUBURU Appoints Brian Knaley as new CEONUBURU Appoints Brian Knaley as new CEO
benzinga.com - November 1 at 5:27 PM
Open Letter to ViewRay Customers, Service, Software Engineers and Suppliers-Lets Preserve ViewRay TechnologyOpen Letter to ViewRay Customers, Service, Software Engineers and Suppliers-Let's Preserve ViewRay Technology
tmcnet.com - October 19 at 8:02 AM
Letter to ViewRay Lenders/Investment Bankers and Customers From Krishnan Suthanthiran, President/Founder of TeamBest Global CompaniesLetter to ViewRay Lenders/Investment Bankers and Customers From Krishnan Suthanthiran, President/Founder of TeamBest Global Companies
benzinga.com - October 17 at 1:37 PM
ViewRay Inc (6L9.BE)ViewRay Inc (6L9.BE)
ca.finance.yahoo.com - August 20 at 6:13 PM
B. Riley Securities downgrades ViewRay Inc. (VRAY) rating to a NeutralB. Riley Securities downgrades ViewRay Inc. (VRAY) rating to a Neutral
knoxdaily.com - July 24 at 3:24 PM
ViewRay stock to be delisted from Nasdaq and moved to OTC ExchangeViewRay stock to be delisted from Nasdaq and moved to OTC Exchange
seekingalpha.com - July 21 at 6:20 PM
ViewRay® Announces Commencement of Nasdaq Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC MarketsViewRay® Announces Commencement of Nasdaq Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Markets
finance.yahoo.com - July 21 at 6:20 PM
Keeping an Eye on ViewRay Inc. (VRAY) After Insider Trading ActivityKeeping an Eye on ViewRay Inc. (VRAY) After Insider Trading Activity
knoxdaily.com - July 19 at 1:18 PM
Why ViewRay Stock Hit A New 52-Week Low TodayWhy ViewRay Stock Hit A New 52-Week Low Today
benzinga.com - July 18 at 8:33 PM
ViewRay, Inc.: ViewRay Files Voluntary Chapter 11 PetitionsViewRay, Inc.: ViewRay Files Voluntary Chapter 11 Petitions
finanznachrichten.de - July 18 at 10:32 AM
Why ViewRay (VRAY) Stock Hit A New 52-Week Low TodayWhy ViewRay (VRAY) Stock Hit A New 52-Week Low Today
msn.com - July 17 at 1:15 PM
Why Is ViewRay (VRAY) Stock Down 69% Today?Why Is ViewRay (VRAY) Stock Down 69% Today?
investorplace.com - July 17 at 12:04 PM
ViewRay® Files Voluntary Chapter 11 PetitionsViewRay® Files Voluntary Chapter 11 Petitions
finance.yahoo.com - July 17 at 8:15 AM
ViewRay Inc. (VRAY) may enjoy gains as insiders got busy in the recent daysViewRay Inc. (VRAY) may enjoy gains as insiders got busy in the recent days
knoxdaily.com - July 12 at 5:59 PM
ViewRay: Near-Term Bankruptcy Filing Might Be In The Cards - SellViewRay: Near-Term Bankruptcy Filing Might Be In The Cards - Sell
msn.com - July 7 at 9:16 AM
Analyzing ViewRay Inc. (VRAY) After Recent Trading ActivityAnalyzing ViewRay Inc. (VRAY) After Recent Trading Activity
knoxdaily.com - July 5 at 8:52 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Cutera logo

Cutera

NASDAQ:CUTR
Cutera, Inc. provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for deep dermal remodeling; truFlex, a bio-electrical muscle stimulation device to treat patients at all fitness levels; and excel V+, a vascular and benign pigmented lesion treatment platform. It also offers truSculpt, a high-powered radio frequency system designed for circumferential reduction, lipolysis, and deep tissue heating and treat all body and skin types; Secret RF, a fractional RF microneedling device that delivers heat into the deeper layers of the skin using controlled RF energy; and enlighten, a laser platform with a dual wavelength for multi-colored tattoo removal, and the treatment of benign pigmented lesions and acne scars. In addition, the company provides excel HR, a hair removal solution for all skin types; and xeo, a multi-application platform for the removal of unwanted hair, treatment of vascular lesions, and skin revitalization by treating discoloration, fine lines, and laxity. Further, it offers its products through direct sales and services, and network of distributors and direct international sales. Cutera, Inc. was incorporated in 1998 and is headquartered in Brisbane, California.
FONAR logo

FONAR

NASDAQ:FONR
FONAR Corporation, together with its subsidiaries, engages in the research, development, production, and marketing of magnetic resonance imaging (MRI) scanners for the detection and diagnosis of human diseases in the United States. The company operates in two segments, Medical Equipment, and Physician Management and Diagnostic Services. It provides Upright MRI scanner that allows patients to be scanned in weight-bearing conditions, such as standing, sitting, bending, or lying down. The company also offers non-medical management, including administrative services, billing and collection services, credentialing services, contract negotiations, compliance consulting, purchasing IT services, hiring, conducting interviews, training, supervision and management of non-medical personnel, storage of medical records, office space, equipment, repair maintenance services, accounting, assistance with compliance matters, and development and implementation of practice growth and marketing strategies. It owns and operates diagnostic imaging facilities in Florida; and manages MRI scanning facilities. The company markets its scanners to private diagnostic imaging centers and hospital outpatient imaging facilities. FONAR Corporation was founded in 1970 and is based in Melville, New York.
Soleno Therapeutics logo

Soleno Therapeutics

NASDAQ:SLNO
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
ViewRay logo

ViewRay

NASDAQ:VRAY
ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, Italy, France, Taiwan, the United Kingdom, and internationally. It provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers through a network of direct sales force and distributors. ViewRay, Inc. was founded in 2004 and is headquartered in Denver, Colorado.